Date receipt dossier
EudraCT number
2004-001250-91
Company / Sponsor
GenVec, Inc.
Phase
II
Treated organism
Humans
Indication category
Cardiovascular therapy
Disease
Stable angina pectoris
Therapeutic approach
Gene therapy
Genetic modification
human VEGF121
Method of transfer of nucleic acid of interest
Human Adenovirus serotype 5
Administered biological material
Recombinant Adenovirus D (E1a and partially E1b and E3)
Route of administration
Intracardiac
Locations in Belgium
AZ Middelheim, Antwerpen
Type of procedure
Contained use only
Notes
study withdrawn by notifier
Pharmaceutical study code
GV-002.001 (NOVA trial)